The Safety and Intraocular Pressure-Lowering Efficacy of Brimonidine Tartrate 0.15% Preserved with Polyquaternium-1

Jess T. Whitson, Katherine I. Ochsner, Marlene R. Moster, E. Kenneth Sullivan, Russell M. Andrew, Lewis H. Silver, David T. Wells, John E. James, Charles F. Bosworth, Jaime E. Dickerson, Theresa A. Landry, Michael V W Bergamini

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: The safety and intraocular pressure (IOP)-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1 were evaluated and compared with brimonidine tartrate 0.15% preserved with chlorine dioxide in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Design: Randomized, double-masked, parallel group, multicenter equivalence study. Participants: Eight hundred forty-two patients randomized to the study treatments. Methods: Patients with OAG or OHT and with qualifying IOP (22-36 mmHg at 8 am on 2 eligibility visits after an appropriate washout period from previous treatment) were assigned randomly to either brimonidine tartrate 0.15% preserved with polyquaternium-1 (brimonidine PQ) or brimonidine tartrate 0.15% preserved with chlorine dioxide (brimonidine P) dosed 3 times daily and were followed up for 6 months. Approximately one half of the study sites continued to follow up their patients for an additional 6 months to obtain longer-term safety data. Results: Brimonidine PQ produced statistically significant and clinically relevant reductions from baseline ranging from 4.3 to 6.5 mmHg, which were statistically and clinically equivalent to brimonidine P at all 18 visit days and times. No safety concerns were identified based on an assessment of ocular and cardiovascular parameters. Patient discontinuations resulting from adverse events were similar for both groups and most of these were a result of signs or symptoms of ocular allergic reaction. Conclusions: Brimonidine PQ is equivalent in IOP-lowering efficacy and safety to brimonidine P.

Original languageEnglish (US)
Pages (from-to)1333-1339
Number of pages7
JournalOphthalmology
Volume113
Issue number8
DOIs
StatePublished - Aug 2006

Fingerprint

Intraocular Pressure
Safety
Ocular Hypertension
Open Angle Glaucoma
polyquaternium 1
Brimonidine Tartrate
Multicenter Studies
Signs and Symptoms
Hypersensitivity
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Whitson, J. T., Ochsner, K. I., Moster, M. R., Sullivan, E. K., Andrew, R. M., Silver, L. H., ... Bergamini, M. V. W. (2006). The Safety and Intraocular Pressure-Lowering Efficacy of Brimonidine Tartrate 0.15% Preserved with Polyquaternium-1. Ophthalmology, 113(8), 1333-1339. https://doi.org/10.1016/j.ophtha.2006.03.025

The Safety and Intraocular Pressure-Lowering Efficacy of Brimonidine Tartrate 0.15% Preserved with Polyquaternium-1. / Whitson, Jess T.; Ochsner, Katherine I.; Moster, Marlene R.; Sullivan, E. Kenneth; Andrew, Russell M.; Silver, Lewis H.; Wells, David T.; James, John E.; Bosworth, Charles F.; Dickerson, Jaime E.; Landry, Theresa A.; Bergamini, Michael V W.

In: Ophthalmology, Vol. 113, No. 8, 08.2006, p. 1333-1339.

Research output: Contribution to journalArticle

Whitson, JT, Ochsner, KI, Moster, MR, Sullivan, EK, Andrew, RM, Silver, LH, Wells, DT, James, JE, Bosworth, CF, Dickerson, JE, Landry, TA & Bergamini, MVW 2006, 'The Safety and Intraocular Pressure-Lowering Efficacy of Brimonidine Tartrate 0.15% Preserved with Polyquaternium-1', Ophthalmology, vol. 113, no. 8, pp. 1333-1339. https://doi.org/10.1016/j.ophtha.2006.03.025
Whitson, Jess T. ; Ochsner, Katherine I. ; Moster, Marlene R. ; Sullivan, E. Kenneth ; Andrew, Russell M. ; Silver, Lewis H. ; Wells, David T. ; James, John E. ; Bosworth, Charles F. ; Dickerson, Jaime E. ; Landry, Theresa A. ; Bergamini, Michael V W. / The Safety and Intraocular Pressure-Lowering Efficacy of Brimonidine Tartrate 0.15% Preserved with Polyquaternium-1. In: Ophthalmology. 2006 ; Vol. 113, No. 8. pp. 1333-1339.
@article{e672933df0c14298805564d75a83ed0b,
title = "The Safety and Intraocular Pressure-Lowering Efficacy of Brimonidine Tartrate 0.15{\%} Preserved with Polyquaternium-1",
abstract = "Purpose: The safety and intraocular pressure (IOP)-lowering efficacy of brimonidine tartrate 0.15{\%} preserved with polyquaternium-1 were evaluated and compared with brimonidine tartrate 0.15{\%} preserved with chlorine dioxide in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Design: Randomized, double-masked, parallel group, multicenter equivalence study. Participants: Eight hundred forty-two patients randomized to the study treatments. Methods: Patients with OAG or OHT and with qualifying IOP (22-36 mmHg at 8 am on 2 eligibility visits after an appropriate washout period from previous treatment) were assigned randomly to either brimonidine tartrate 0.15{\%} preserved with polyquaternium-1 (brimonidine PQ) or brimonidine tartrate 0.15{\%} preserved with chlorine dioxide (brimonidine P) dosed 3 times daily and were followed up for 6 months. Approximately one half of the study sites continued to follow up their patients for an additional 6 months to obtain longer-term safety data. Results: Brimonidine PQ produced statistically significant and clinically relevant reductions from baseline ranging from 4.3 to 6.5 mmHg, which were statistically and clinically equivalent to brimonidine P at all 18 visit days and times. No safety concerns were identified based on an assessment of ocular and cardiovascular parameters. Patient discontinuations resulting from adverse events were similar for both groups and most of these were a result of signs or symptoms of ocular allergic reaction. Conclusions: Brimonidine PQ is equivalent in IOP-lowering efficacy and safety to brimonidine P.",
author = "Whitson, {Jess T.} and Ochsner, {Katherine I.} and Moster, {Marlene R.} and Sullivan, {E. Kenneth} and Andrew, {Russell M.} and Silver, {Lewis H.} and Wells, {David T.} and James, {John E.} and Bosworth, {Charles F.} and Dickerson, {Jaime E.} and Landry, {Theresa A.} and Bergamini, {Michael V W}",
year = "2006",
month = "8",
doi = "10.1016/j.ophtha.2006.03.025",
language = "English (US)",
volume = "113",
pages = "1333--1339",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - The Safety and Intraocular Pressure-Lowering Efficacy of Brimonidine Tartrate 0.15% Preserved with Polyquaternium-1

AU - Whitson, Jess T.

AU - Ochsner, Katherine I.

AU - Moster, Marlene R.

AU - Sullivan, E. Kenneth

AU - Andrew, Russell M.

AU - Silver, Lewis H.

AU - Wells, David T.

AU - James, John E.

AU - Bosworth, Charles F.

AU - Dickerson, Jaime E.

AU - Landry, Theresa A.

AU - Bergamini, Michael V W

PY - 2006/8

Y1 - 2006/8

N2 - Purpose: The safety and intraocular pressure (IOP)-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1 were evaluated and compared with brimonidine tartrate 0.15% preserved with chlorine dioxide in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Design: Randomized, double-masked, parallel group, multicenter equivalence study. Participants: Eight hundred forty-two patients randomized to the study treatments. Methods: Patients with OAG or OHT and with qualifying IOP (22-36 mmHg at 8 am on 2 eligibility visits after an appropriate washout period from previous treatment) were assigned randomly to either brimonidine tartrate 0.15% preserved with polyquaternium-1 (brimonidine PQ) or brimonidine tartrate 0.15% preserved with chlorine dioxide (brimonidine P) dosed 3 times daily and were followed up for 6 months. Approximately one half of the study sites continued to follow up their patients for an additional 6 months to obtain longer-term safety data. Results: Brimonidine PQ produced statistically significant and clinically relevant reductions from baseline ranging from 4.3 to 6.5 mmHg, which were statistically and clinically equivalent to brimonidine P at all 18 visit days and times. No safety concerns were identified based on an assessment of ocular and cardiovascular parameters. Patient discontinuations resulting from adverse events were similar for both groups and most of these were a result of signs or symptoms of ocular allergic reaction. Conclusions: Brimonidine PQ is equivalent in IOP-lowering efficacy and safety to brimonidine P.

AB - Purpose: The safety and intraocular pressure (IOP)-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1 were evaluated and compared with brimonidine tartrate 0.15% preserved with chlorine dioxide in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Design: Randomized, double-masked, parallel group, multicenter equivalence study. Participants: Eight hundred forty-two patients randomized to the study treatments. Methods: Patients with OAG or OHT and with qualifying IOP (22-36 mmHg at 8 am on 2 eligibility visits after an appropriate washout period from previous treatment) were assigned randomly to either brimonidine tartrate 0.15% preserved with polyquaternium-1 (brimonidine PQ) or brimonidine tartrate 0.15% preserved with chlorine dioxide (brimonidine P) dosed 3 times daily and were followed up for 6 months. Approximately one half of the study sites continued to follow up their patients for an additional 6 months to obtain longer-term safety data. Results: Brimonidine PQ produced statistically significant and clinically relevant reductions from baseline ranging from 4.3 to 6.5 mmHg, which were statistically and clinically equivalent to brimonidine P at all 18 visit days and times. No safety concerns were identified based on an assessment of ocular and cardiovascular parameters. Patient discontinuations resulting from adverse events were similar for both groups and most of these were a result of signs or symptoms of ocular allergic reaction. Conclusions: Brimonidine PQ is equivalent in IOP-lowering efficacy and safety to brimonidine P.

UR - http://www.scopus.com/inward/record.url?scp=33746285117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746285117&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2006.03.025

DO - 10.1016/j.ophtha.2006.03.025

M3 - Article

C2 - 16877072

AN - SCOPUS:33746285117

VL - 113

SP - 1333

EP - 1339

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 8

ER -